Oleoylethanolamide (OEA) is a lipid the body makes naturally, described as endocannabinoid-like. As a supplement it has been studied for weight, appetite and metabolic health.
Also known as: OEA.
An 8-week trial used 125 mg twice a day (Ostadrahimi 2024). These are study protocols, not a recommendation.
It is sold in the US as a dietary supplement. Under the 1994 dietary supplement law (DSHEA), FDA does not approve dietary supplements before they are marketed, and the maker, not FDA, is responsible for safety and labeling. It is not an FDA-approved weight-loss drug.
What studies show: a 2025 meta-analysis of 10 trials found OEA improved weight, BMI, waist size, fat mass, triglycerides, blood sugar, insulin and some inflammation markers, but not cholesterol, HbA1c or fat-free mass; the authors said more research is needed before firm conclusions (Bahari 2025). In an 8-week placebo-controlled trial in 60 adults with obesity, 125 mg twice a day lowered triglycerides (from about 166 to 142 mg/dL), with no change in cholesterol, blood sugar or eating habits (Ostadrahimi 2024).
Safety: the sources here do not describe side effects or drug interactions.
We could not find a single published half-life or time to peak for OEA that applies to a supplement dose, so we do not list one.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator